Literature DB >> 2311062

Metastatic epidural spinal cord compression. Results of treatment and survival.

S Sørensen1, S E Børgesen, K Rohde, B Rasmusson, F Bach, T Bøge-Rasmussen, P Stjernholm, B H Larsen, N Agerlin, F Gjerris.   

Abstract

All medical records of patients treated for metastatic compression of the spinal cord or cauda equina in the eastern part of Denmark from 1979 through 1985 were reviewed. With regard to treatment response and survival, 345 patients could be evaluated. Carcinoma of the lung (19%), prostate (18%), breast (13%), and kidney (10%) were the most frequent primary malignancies causing spinal compression. The outcome of treatment depended primarily on the patients' condition at the time of diagnosis: 79% of the patients who were able to walk before the treatment remained ambulatory, whereas only 21% of the nonambulatory paraplegic patients and 6% of the paralytic patients regained walking ability. Patients treated with laminectomy followed by radiotherapy seemed to respond better than patients treated with radiotherapy or laminectomy alone, but when the patients' pretreatment motor function was taken into account no significant difference was found between the three forms of treatment. In the subgroup of nonambulatory patients, however, a significantly better restoration of gait was observed in patients treated with the combination of laminectomy and radiotherapy than in patients treated with radiotherapy alone. A longer survival in the group treated with the combination of laminectomy and radiotherapy may reflect that these patients were in a lower stage of disease and thus had a better potential of regaining motor function. The results call for prospective randomized studies.

Entities:  

Mesh:

Year:  1990        PMID: 2311062     DOI: 10.1002/1097-0142(19900401)65:7<1502::aid-cncr2820650709>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal.

Authors:  S Helweg-Larsen; A Wagner; L Kjaer; A Johnsen; J Boesen; T Palner; P S Sørensen
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

2.  Early diagnosis and treatment of spinal epidural metastasis in breast cancer: a prospective study.

Authors:  W Boogerd; J J van der Sande; R Kröger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

3.  A meta-analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease.

Authors:  Paul Klimo; Clinton J Thompson; John R W Kestle; Meic H Schmidt
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

Review 4.  [Compression syndromes].

Authors:  J Wierecky; C Bokemeyer
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 5.  Neurology.

Authors:  A N Gale; J M Gibbs; A H Schapira; P K Thomas
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

6.  Paraplegia of spinal epidural compression by metastatic breast cancer and urgent radiotherapy-timeliness for naught?

Authors:  Federico L Ampil; Roxana Baluna; Gary Burton; Anil Nanda
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

7.  Surgery of cervical spine metastases: a retrospective study.

Authors:  B Jónsson; H Jónsson; G Karlström; L Sjöström
Journal:  Eur Spine J       Date:  1994       Impact factor: 3.134

Review 8.  Surgery for metastatic spinal disease.

Authors:  W C Welch; G B Jacobs
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Spinal cord compression in prostate cancer.

Authors:  J L Osborn; R H Getzenberg; D L Trump
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Development and validation of a prognostic nomogram for the overall survival of patients living with spinal metastases.

Authors:  Xiong-Gang Yang; Jiang-Tao Feng; Feng Wang; Xin He; Hao Zhang; Li Yang; Hao-Ran Zhang; Yong-Cheng Hu
Journal:  J Neurooncol       Date:  2019-09-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.